Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Newly identified rare genetic variant reduces the risk of leukemia

A newly identified and rare genetic variant slows the growth of mutated blood stem cells, researchers report, and it reduces the risk of leukemia.

2 Jan 2026

Combination therapy offers hope for AML patients facing drug resistance

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

30 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation.

12 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

Black patients with AML experience earlier onset and poorer outcomes

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health.

7 Dec 2025

A new generation of AML treatments brings hope for better survival

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates.

1 Dec 2025

New medication offers potential treatment for patients with deadliest form of blood cancer

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.

25 Nov 2025

Young donor age proves critical for survival after stem cell transplantation

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT).

21 Nov 2025

St. Jude scientists identify new therapeutic target for high-risk pediatric leukemia

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in urgent need of novel therapeutic options.

3 Nov 2025

Dysfunction in chromosome-stabilizing protein identified as a cause of deadly illnesses

New research from the University of Wisconsin–Madison reveals that dysfunction in a protein essential to maintaining stability in our chromosomes may be responsible for serious - and sometimes deadly - diseases.

31 Oct 2025

Research shows the potential of structural nanomedicine in cancer treatment

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and effective and less toxic.

29 Oct 2025

Scientists discover why a powerful leukemia drug fails in most patients

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

17 Oct 2025

Age alone may not predict outcomes in acute myeloid leukemia

An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic.

14 Oct 2025

Targeting aggressive childhood leukemia with nanobody PROTACs

Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukemia.

13 Oct 2025

DKMS advances blood cancer research with groundbreaking ASAP study

The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts.

6 Oct 2025